Categorynews

Shaolian Zhou, Ph.D., Joins Worldwide Clinical Trials as Senior Vice President and Lab Director for Bioanalytical Services

March 26, 2019 Off By BusinessWire

MORRISVILLE, N.C.–(BUSINESS WIRE)–Worldwide
Clinical Trials, Inc. (Worldwide), an award-winning, full-service,
midsize, global CRO, announced today that Shaolian Zhou, Ph.D., has
joined the company as senior vice president and lab director for
Bioanalytical Services. Based at the company’s Austin, Texas,
Bioanalytic Laboratory, Dr. Zhou is responsible for the overall
operations of the facility. He serves as a scientific and technical
advisor for clients and internal teams, overseeing the generation of
quality assays, data and reports, as well as compliance with all
scientific and technical goals and regulatory requirements.

“With a strong background in analytical chemistry, bioanalytical
sciences and clinical trials, Shaolian adds invaluable expertise to our
Bioanalytical Services portfolio – especially for emerging
pharmaceutical and biotech companies seeking the attention, insight and
prioritization that isn’t reciprocated by large, consolidating CROs,”
said Peter Benton, president and COO, Worldwide Clinical Trials. “His
experience with personalized medicine and innovative therapies further
extends our commitment to deliver uncommon expertise from the very onset
of their drug development journey.”

Prior to joining Worldwide, Dr. Zhou served as the global head of Small
Molecule Bioanalytical Research and Development for Roche Research and
Early Development (pRED). He worked with Novartis Institutes for
Biomedical Research as site head of Analytical Sciences and Research
Investigator of Metabolism and Pharmacokinetics. He also brings over
four years of CRO experience working as a method development manager at
Covance Laboratories.

Zhou received his Doctor of Philosophy in analytical chemistry from the
University of Tennessee in Knoxville, Tennessee, and conducted his
post-doctoral research at the University of Utah in Salt Lake City,
Utah. Prior to graduate school, he completed his Bachelor of Science
degree in chemistry at Nanjing University.

“Throughout my 20 years of experience in the drug development industry,
I’ve been fortunate to acquire a combined expertise in both small and
large molecule bioanalysis,” said Dr. Zhou. “With that said, I am
excited to play a role in Worldwide’s development of strategic
methodologies to facilitate the successful development of therapies that
could be transformative to patients’ lives.”

For more information on Dr. Zhou and the expanding Worldwide team, visit www.worldwide.com.

About Worldwide Bioanalytical Services

From discovery to post-marketing, Worldwide partners with pharmaceutical
and biotech sponsors to develop custom method transfer/optimize and
validate existing method, identify liabilities and de-risk regulated
assays, or adapt methods to increase efficiency and cost-effectiveness
in both non-GLP and GLP/GCP bioanalysis.

Worldwide scientists routinely analyze more than 30,000 samples per
month and have demonstrated capability of up to 45,000 samples per month.

With state-of-the-art bioanalytical instrumentation and more than 2,500
validated assays, Worldwide is at the forefront of the industry in the
development of bioanalytical methodology.

In addition to its established capability, Worldwide is developing a
LC-MS based platform for both small molecule and protein/peptide
biomarkers, enabling drug development support for personalized medicine.

About Worldwide Clinical Trials

Worldwide Clinical Trials employs more than 1,600 professionals around
the world, with offices in North and South America, Eastern and Western
Europe, Russia, and Asia. Founded by physicians committed to advancing
medical science, Worldwide is out to change how the world experiences
CROs – in the best possible way. From early phase and bioanalytical
sciences through late phase, post-approval and real-world evidence, we
provide world-class, full-service drug development services.

With infrastructure and talent spanning 60 countries, we execute
predictable, successful studies with operational excellence across a
range of therapeutic areas, including central nervous system,
cardiovascular, metabolic, immune-mediated inflammatory disorders
(IMID), oncology and rare diseases. We never compromise on science or
safety. We’re never satisfied with the status quo. We’re the Cure for
the Common CRO.

For more information, visit http://www.worldwide.com.